2023-05-03 09:14:05 ET
- Femasys' ( NASDAQ: FEMY ) endocervical tissue sampler FemCerv received product approval from Health Canada and the Public Health Agency of Canada.
- FEMY is up ~10% before the bell.
- FemCerv is designed to collect and contain a comprehensive sample to maximize quality and quantity.
- FemCerv captures tissue sample with minimal pain and has the potential to improve the standard of care for diagnosing cervical cancer.
- FemCerv is designed to be used with colposcopy and capture a comprehensive 360-degree tissue sample in a pain-free office visit, maximizing quality and quantity.
- Press Release
For further details see:
Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada, stock rises 10%